SWP
BLCM

Stratos Wealth Partners’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Stratos Wealth Partners’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9
Closed -$1K – 2767
2018
Q1 		$1K Buy
+9
New +$680 ﹤0.01% 3058

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stratos Wealth Partners's BLCM Position: Q2 2018 in Review

Stratos Wealth Partners sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 9 shares — an estimated $1K sold.

Stratos Wealth Partners first reported a position in BLCM in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

  • Stratos Wealth Partners reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 9 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $1K.
  • Stratos Wealth Partners first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Stratos Wealth Partners's Bellicum Pharmaceuticals, Inc. position peaked at $1K in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on Stratos Wealth Partners's 13F filing for Q2 2018, filed 13 Aug 2018.